[1] 范建高,曾静. 非酒精性脂肪性肝病的流行现状与危害. 中华消化杂志,2020,40(9):10-13. [2] Jing L,Qian C,Jing Y, et al. IFN-γ contributes to the hepatic inflammation in HFD-induced nonalcoholic steatohepatitis by STAT1β/TLR2 signaling pathway. Mol Immunol,2021,134(18):118-128. [3] 金虎,江克清,钟伏弟,等. 非酒精性脂肪性肝炎治疗研究进展. 中华实验外科杂志, 2021,38(10):2055-2060. [4] Yin Y,Liu H,Zheng Z ,et al. Genistein can ameliorate hepatic inflammatory reaction in nonalcoholic steatohepatitis rats. Biomed Pharmacot,2019,111(29):1290-1296. [5] 阮雄中,陈压西. 代谢性炎症与非酒精性脂肪性肝病的发生与发展. 中华消化杂志, 2020,40(9):581-584. [6] Bai R,Xu Y,Qin G, et al. Repression of TXNIP–NLRP3 axis restores intestinal barrier function via inhibition of myeloperoxidase activity and oxidative stress in nonalcoholic steatohepatitis. J Cell Physiol,2019,234(5):7524-7538. [7] 饶紫兰,陈聪杰,胡俊,等. NOD样受体家族3基因敲除对改善非酒精性脂肪性肝炎小鼠肝损伤及脂代谢的影响. 中国临床药理学杂志, 2021,37(16):2217-2220. [8] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年1月修订). 中华内科杂志,2010,49(3):275-278. [9] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师煳旨肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版). 中华肝脏病杂志,2018, 26(3):195-203. [10] Sun G,Zhao X,Li M ,et al. CD4 derived double negative T cells prevent the development and progression of nonalcoholic steatohepatitis. Nature Commun, 2021,12(1):650-652. [11] 方菊梅,张万里,陈怡发,等. 非酒精性脂肪性肝炎患者血清sCD163和IL-1βmRNA水平变化及其临床意义探讨. 实用肝脏病杂志, 2020,23(3):368-371. [12] 陈丽丽, 符茂雄, 刘正金,等. 非酒精性脂肪性肝炎患者血清成纤维细胞生长因子-21和脂联素水平变化及其临床意义探讨. 实用肝脏病杂志, 2020, 23(5):658-661. [13] Slater T F,Cheeseman K H,Benedetto C,et al. Studies on the hyperplasia (regeneration) of the rat liver following partial hepatectomy. Changes in lipid peroxidation and general biochemical aspects. Biochem J, 2019, 265(1):51-59. [14] Liu Y,Li Y P,Xiao L M,et al. Extracellular vesicles derived from M2 microglia reduce ischemic brain injury through microRNA-135a-5p/TXNIP/NLRP3 axis. Lab Invest, 2021,101(7):1-14. [15] 万小雨,曾俊豪,张婉怡,等. 非酒精性脂肪性肝炎小鼠模型的建立. 中国免疫学杂志, 2020,36(16):1925-1930. [16] Zhu L Y,Liu C,Li Z R,et al. NLRP3 deficiency did not attenuate NASH development under high fat calorie diet plus high fructose and glucose in drinking water. Lab Invest, 2021,101(5):588-599. [17] Cao G,Nan J,Hu Y,et al. Ruscogenin attenuates cerebral ischemia-induced blood-brain barrier dysfunction by suppressing TXNIP/NLRP3 inflammasome activation and the MAPK pathway. Int J Mol Ences, 2016,17(9):1418-1419. [18] Loomba R,Mohseni R,Lucas K J,et al. TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial. Gastroenterology, 2021, 161(5):1475-1486. [19] Huang H M, SJ Fan, Zhou X R,et al. Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis. Acta Pharmacol Sin, 2021,43(4):941-953. [20] Glass O, Henao R, Patel K,et al. Serum interleukin-8, osteopontin, and monocyte chemoattractant protein 1 are associated with hepatic fibrosis in patients with nonalcoholic fatty liverdDisease. Hepatol Commun, 2018, 2(11):1344-1355. |